Scil Proteins GmbH Successfully Completes Manufacture of Recombinant Protein Candidate for Lundbeck Inc.

Published: Nov 15, 2011

HALLE, Germany--(BUSINESS WIRE)--Scil Proteins, a private biotech company specialized in the research, development and production of recombinant proteins, announced today the successful completion of a manufacturing agreement for Lundbeck, an international pharmaceutical company specializing in central nervous system disorders. Scil Proteins was responsible for the process development and early stage GMP manufacturing for a recombinant protein candidate. Financial terms were not disclosed.

Back to news